Related Experiment Videos

Amyloid protein precursor messenger RNAs: differential expression in Alzheimer's disease

M R Palmert1, T E Golde, M L Cohen

  • 1Division of Neuropathology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106.

Science (New York, N.Y.)
|August 26, 1988
PubMed

Insights

Researchers found increased amyloid precursor protein (APP) mRNA lacking the Kunitz protease inhibitor (KPI) domain in specific brain regions of Alzheimer's disease (AD) patients. This suggests a key role for this altered APP form in AD pathogenesis.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pathology

Background:

  • Alzheimer's disease (AD) is characterized by amyloid plaque deposition.
  • Amyloid precursor protein (APP) is a key protein implicated in AD pathogenesis.
  • The role of different APP mRNA isoforms in AD is not fully understood.

Purpose of the Study:

  • To investigate the levels of total APP mRNA and APP mRNA with the Kunitz protease inhibitor (KPI) insert in Alzheimer's disease brains.
  • To determine the specific neuronal populations affected by changes in APP mRNA expression in AD.

Main Methods:

  • In situ hybridization was employed to quantify APP mRNA in neurons from Alzheimer's disease and control brains.
  • Analysis focused on specific brain regions including the nucleus basalis, locus ceruleus, hippocampus, basis pontis, and occipital cortex.

Main Results:

  • A significant twofold increase in total APP mRNA was observed in nucleus basalis and locus ceruleus neurons in AD brains compared to controls.
  • This increase was exclusively attributed to APP mRNA lacking the KPI domain.
  • No significant changes in total APP mRNA were found in hippocampal, basis pontis, or occipital cortical neurons.

Conclusions:

  • Increased production of APP mRNA lacking the KPI domain in nucleus basalis and locus ceruleus neurons may contribute to cerebral amyloid deposition in Alzheimer's disease.
  • These findings highlight the potential importance of specific APP isoforms in AD neurodegeneration.
  • Targeting APP mRNA lacking the KPI domain could be a therapeutic strategy for AD.

Related Concept Videos